Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
In the citing paper
“Risedronate reduces the incidence of vertebral fractures by 41 to 49 % and nonvertebral fractures by 36 % over 3 years, with significant risk reduction occurring within 1 year of treatment in patients with a prior vertebral fracture [51, 52].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [52]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 810
Estrogen Replacement Therapy and Fractures in Older Women
Cauley, J. A., Seeley, D. G., Ensrud, K., Ettinger, B., Black, D., Cummings, S. R., & and For The Study of Osteoporotic Fractures Research Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 809
Serum vitamin D concentrations among elderly people in Europe
van der Wielen, R. P. J., de Groot, L. C. P. G. M., van Staveren, W. A., Löwik, M. R. H., van den Berg, H., Haller, J., & Moreiras, O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91266-5 · Cited by 772
Esophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Self-citationGenant, H. K., Grampp, S., Glüer, C. C., Faulkner, K. G., Jergas, M., Engelke, K., Hagiwara, S., & van Kuijk, C. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650091002 · Cited by 610
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Self-citationFRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0543-5 · Cited by 2,467
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“vertebral and non-vertebral fractures by 40–50% and 30– 36%, respectively, in women with prevalent vertebral fractures [212, 213].”
BackgroundSelf-citationRisk of New Vertebral Fracture in the Year Following a Fracture
Lindsay, R. (2001) · JAMA · doi:10.1001/jama.285.3.320 · Cited by 1,897
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Black, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,712
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
Self-citationRomosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Self-citationThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Kanis, J. A., Oden, A., Johnell, O., Johansson, H., De Laet, C., Brown, J., Burckhardt, P., Cooper, C., Christiansen, C., Cummings, S., et al. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0343-y · Cited by 1,224
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
“5 or lower in the spine, femoral neck, total hip, or 1/3 radius (189,193,194,196205).”
InfluentialSambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Bisphosphonates: The first 40years
Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2011.04.022 · Cited by 1,124
Reginster, J. Y., Seeman, E., De Vernejoul, M. C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J. P., Curiel, M. D., Sawicki, A., Goemaere, S., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1774 · Cited by 1,071
Self-citationSelective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
Riggs, B. L., & Hartmann, L. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022219 · Cited by 968
UK clinical guideline for the prevention and treatment of osteoporosis
The National Osteoporosis Guideline Group (NOGG), Compston, J., Cooper, A., Cooper, C., Gittoes, N., Gregson, C., Harvey, N., Hope, S., Kanis, J. A., McCloskey, E. V., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0324-5 · Cited by 826
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Self-citationCummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Osteoporosis: A Review of Treatment Options.
Tu, K. N., Lie, J. D., Wan, C. K. V., Cameron, M., Austel, A. G., Nguyen, J. K., Van, K., & Hyun, D. (2018) · PubMed Central · Cited by 735
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 718
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 704
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialAdler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 672
Hodgson, S. F., Watts, N. B., Bilezikian, J. P., Clarke, B. L., Gray, T. K., Harris, D. W., Conrad Johnston, C., Kleerekoper, M., Lindsay, R., Luckey, M. M., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.6.544 · Cited by 605
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Kanis, J. A., McCloskey, E. V., Johansson, H., Strom, O., Borgstrom, F., Oden, A., & National Osteoporosis Guideline Group (2008) · Osteoporosis International · doi:10.1007/s00198-008-0712-1 · Cited by 591
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588
Self-citationVan Staa, T. P., Laan, R. F., Barton, I. P., Cohen, S., Reid, D. M., & Cooper, C. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11283 · Cited by 559
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Ström, O., Borgström, F., Kanis, J. A., Compston, J., Cooper, C., McCloskey, E. V., & Jönsson, B. (2011) · Archives of Osteoporosis · doi:10.1007/s11657-011-0060-1 · Cited by 546
Delmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545
Long-Term Use of Bisphosphonates in Osteoporosis
Watts, N. B., & Diab, D. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1947 · Cited by 542
ASIPP, A. (2007) · Pain Physician · doi:10.36076/ppj.2007/10/7 · Cited by 519
Wallach, S., Cohen, S., Reid, D. M., Hughes, R. A., Hosking, D. J., Laan, R. F., Doherty, S. M., Maricic, M., Rosen, C., Brown, J., et al. (2000) · Calcified Tissue International · doi:10.1007/s002230001146 · Cited by 513
Silverman, S. L., Christiansen, C., Genant, H. K., Vukicevic, S., Zanchetta, J. R., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 508
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Wells, G. A., Cranney, A., Peterson, J., Boucher, M., Shea, B., Welch, V., Coyle, D., & Tugwell, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003376.pub3 · Cited by 499
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.gl · Cited by 478
Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday
McClung, M., Harris, S. T., Miller, P. D., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Kendler, D. L., Yuen, C. K., & Lewiecki, E. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.06.023 · Cited by 451
Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass
McClung, M. R., San Martin, J., Miller, P. D., Civitelli, R., Bandeira, F., Omizo, M., Donley, D. W., Dalsky, G. P., & Eriksen, E. F. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1762 · Cited by 444
Watts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack, R. P., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 441
Fracture risk following an osteoporotic fracture
Johnell, O., Kanis, J. A., Odén, A., Sernbo, I., Redlund-Johnell, I., Petterson, C., De Laet, C., & Jönsson, B. (2004) · Osteoporosis International · doi:10.1007/s00198-003-1514-0 · Cited by 438
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00005 · Cited by 427
McLellan, A. R., Gallacher, S. J., Fraser, M., & McQuillian, C. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1507-z · Cited by 421
Bisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Ettinger, B. B., Harris, S. T., Kendler, D. L., Kessel, B., McClung, M. R., Gorodeski, G. I., Rothert, M. L., Henderson, V. W., Richardson, M. K., Freedman, R. R., et al. (2006) · Cited by 403
Osteoblast proliferation and maturation by bisphosphonates
Im, G.-I., Qureshi, S. A., Kenney, J., Rubash, H. E., & Shanbhag, A. S. (2004) · Biomaterials · doi:10.1016/j.biomaterials.2003.11.024 · Cited by 393
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Eisman, J. A., Bogoch, E. R., Dell, R., Harrington, J. T., McKinney, R. E., McLellan, A., Mitchell, P. J., Silverman, S., Singleton, R., Siris, E., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1698 · Cited by 383
Fracture risk and zoledronic acid therapy in men with osteoporosis
Boonen, S., Reginster, J.-Y., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., Lipschitz, S., Dimai, H. P., Witvrouw, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204061 · Cited by 359
Self-citationChange in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M. L., Eastell, R., Lui, L.-Y., Wu, L. A., de Papp, A. E., Grauer, A., Marin, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 353
Self-citationSeven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis
Mellström, D. D., Sörensen, O. H., Goemaere, S., Roux, C., Johnson, T. D., & Chines, A. A. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0286-7 · Cited by 350
Self-citationRosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345
Risk of subsequent fracture after prior fracture among older women
Balasubramanian, A., Zhang, J., Chen, L., Wenkert, D., Daigle, S. G., Grauer, A., & Curtis, J. R. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4732-1 · Cited by 345
Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study
Häussler, B., Gothe, H., Göl, D., Glaeske, G., Pientka, L., & Felsenberg, D. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0206-y · Cited by 342
Meunier, P. J. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.5.2060 · Cited by 337
Self-citationTaylor, R. S., Taylor, R. J., & Fritzell, P. (2006) · Spine · doi:10.1097/01.brs.0000244639.71656.7d · Cited by 334
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Self-citationEffect of Osteoporosis Treatment on Mortality: A Meta-Analysis
Bolland, M. J., Grey, A. B., Gamble, G. D., & Reid, I. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0852 · Cited by 329
Reginster, J.-Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J. J., Silverman, S. L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044958 · Cited by 326
Prevention and management of osteoporosis
McClung, M. R. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00080-5 · Cited by 321
Vertebral Fractures: Clinical Importance and Management
Kendler, D. L., Bauer, D. C., Davison, K. S., Dian, L., Hanley, D. A., Harris, S. T., McClung, M. R., Miller, P. D., Schousboe, J. T., Yuen, C. K., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.09.020 · Cited by 319
Miller, P. D., Roux, C., Boonen, S., Barton, I. P., Dunlap, L. E., & Burgio, D. E. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050817 · Cited by 318
Self-citationHasserius, R., Karlsson, M. K., Nilsson, B. E., Not Available, I., & Johnell, O. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1316-9 · Cited by 313
Cosman, F., Nieves, J., Woelfert, L., Formica, C., Gordon, S., Shen, V., & Lindsay, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.5.925 · Cited by 311
Osteoporosis in elderly: prevention and treatment
Srivastava, M., & Deal, C. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00022-8 · Cited by 309
Nelson, H. D., Helfand, M., Woolf, S. H., & Allan, J. D. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-6-200209170-00015 · Cited by 295
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., & Oakley, J. (2005) · Health Technology Assessment · doi:10.3310/hta9220 · Cited by 295
Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 290
Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate
Blake, G. M., Park-Holohan, S.-J., Cook, G. J. R., & Fogelman, I. (2001) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2001.18742 · Cited by 286
Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 282
III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Adachi, J., Weaver, B., Zytaruk, N., Papaioannou, A., Robinson, V., Shea, B., Wells, G., & Guyatt, G. (2002) · Endocrine Reviews · doi:10.1210/er.2001-3002 · Cited by 281
(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Reginster, J., Felsenberg, D., Boonen, S., Diez‐Perez, A., Rizzoli, R., Brandi, M., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23461 · Cited by 261
Self-citationPfeifer, M., Begerow, B., & Minne, H. W. (2004) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/01.phm.0000113403.16617.93 · Cited by 261
Self-citationDelmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258
Self-citationSorensen, O. H., Crawford, G. M., Mulder, H., Hosking, D. J., Gennari, C., Mellstrom, D., Pack, S., Wenderoth, D., Cooper, C., & Reginster, J.-Y. (2003) · Bone · doi:10.1016/s8756-3282(02)00946-8 · Cited by 254
Self-citationKimmel, D. B. (2007) · Journal of Dental Research · doi:10.1177/154405910708601102 · Cited by 251
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 249
Self-citationOsteoporosis and fractures in women: the burden of disease
Lorentzon, M., Johansson, H., Harvey, N. C., Liu, E., Vandenput, L., McCloskey, E. V., & Kanis, J. A. (2022) · Climacteric · doi:10.1080/13697137.2021.1951206 · Cited by 241
Cremers, S. C. L. M., Pillai, G. (., & Papapoulos, S. E. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00001 · Cited by 238
Diagnosis and management of vertebral fractures in elderly adults
Papaioannou, A., Watts, N. B., Kendler, D. L., Yuen, C. K., Adachi, J. D., & Ferko, N. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01190-7 · Cited by 237
Osteoporosis and its management
Poole, K. E. S., & Compston, J. E. (2006) · BMJ · doi:10.1136/bmj.39050.597350.47 · Cited by 232
Metadata
- Authors
- Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., & Eastell, R.
- Affiliations
- University of Liège (BE)
- The University of Sydney (AU)
- Hôpital Cochin (FR)
- University of Florence (IT)
- Procter & Gamble (United States) (US)
- University of Sheffield (GB)
- Venue
- Osteoporosis International
- Published
- 2000-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 83-91
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W1526826623
- Cited by
- 1,580
- References
- 29
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 25 · 2022: 26 · 2021: 31 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 27 · 2016: 44 · 2015: 50 · 2014: 47 · 2013: 69 · 2012: 66
- FWCI
- 78.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, postmenopausal osteoporosis, vertebral fractures, fracture prevention, bisphosphonates, bone mineral density, non-vertebral fractures, calcium and vitamin D supplementation, gastrointestinal adverse effects, drug safety
- MeSH terms
- Risedronic Acid, Aged, Aged, 80 and over, Algorithms, Australia, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Middle Aged, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.